CathVision Aims to End Guesswork in Cardiac Ablation with New Tech

COPENHAGEN, Denmark – January 29, 2026 – Danish medtech firm CathVision today announced a significant advance in the treatment of cardiac arrhythmias, unveiling a new software technology designed to provide real-time, objective feedback during a revolutionary procedure known as Pulsed Field Ablation (PFA). The company’s PFAnalyzer™ module, detailed in a new research letter published in the peer-reviewed journal Heart Rhythm, promises to solve a critical “blind spot” in PFA, potentially improving long-term outcomes for patients with atrial fibrillation.

The study, conducted in collaboration with the University Hospital of Split in Croatia and Mount Sinai in New York, demonstrates that the system can detect and interpret ultra-low-voltage electrical signals from the heart, giving doctors a clear, immediate picture of whether their treatment has been successful. This development addresses a growing gap between the rapid adoption of PFA and the ability to verify its effectiveness during the procedure itself.

The PFA Revolution and Its 'Blind Spot'

Pulsed Field Ablation has been hailed as a paradigm shift in electrophysiology. The technique uses short, high-voltage electrical pulses to selectively destroy heart muscle cells causing arrhythmias, while uniquely sparing surrounding tissues like the esophagus and critical nerves. This enhanced safety profile, combined with significantly faster procedure times, has fueled its explosive growth. The global PFA market, valued at nearly $1 billion in 2024, is projected by analysts to soar past $7 billion by 2032.

Industry giants like Medtronic, Boston Scientific, and Abbott have all launched their own PFA systems in the last two years, racing to capture a dominant share of the burgeoning market. Boston Scientific’s FARAPULSE system, for instance, has already captured a significant portion of the global market, while Medtronic’s PulseSelect and Abbott’s Volt systems are rapidly gaining ground.

Despite this widespread enthusiasm and rapid adoption, a fundamental challenge has persisted. Unlike older thermal ablation methods, PFA does not leave an immediate, visible mark on the tissue. Doctors have therefore been forced to rely on surrogate endpoints—indirect measures that suggest, but do not confirm, the creation of a durable lesion. This uncertainty is a major concern, as numerous studies have shown that incomplete ablation and the eventual reconnection of electrical pathways are primary drivers of arrhythmia recurrence, often forcing patients to undergo repeat procedures.

A New Lens on Cardiac Signals

CathVision’s innovation aims to eliminate this procedural guesswork by re-establishing the role of the electrogram—the heart's own electrical signal—as the ultimate source of truth. The company's ECGenius™ EP Recording System is designed for superior signal acquisition, capable of capturing high-fidelity data that is often lost or filtered out by conventional systems. The new PFAnalyzer™ software module then processes these signals to provide actionable insights.

The research published in Heart Rhythm confirms the existence of a clinically meaningful threshold for these signals at an incredibly low amplitude of approximately 0.1 millivolts (mV). Signals in this range, previously considered unusable noise, can now reliably distinguish between successfully ablated tissue (electrical silence) and areas with residual electrical activity that could cause future problems. The system effectively allows physicians to “see” the electrical effect of the ablation in real time.

“What this work shows is that clinically meaningful information is still present in PFA - down to voltage levels we previously could not use,” said Dr. Ante Anić of the University Hospital of Split, a lead researcher on the study. “With high-fidelity unipolar signals and tools like PFAnalyzer, signal analysis in electrophysiology becomes actionable again during the procedure, not just retrospective.”

From Guesswork to Guidance: The Clinical Impact

The ability to receive objective, electrophysiologic feedback during an ablation holds the potential to transform patient outcomes. By confirming complete electrical isolation at the time of the procedure, surgeons can be more confident that they have created durable lesions, directly addressing the primary cause of long-term treatment failure.

This could lead to a significant reduction in the recurrence rates for atrial fibrillation, a condition that affects millions worldwide and is a leading cause of stroke. For patients, this means a lower likelihood of needing costly and stressful repeat procedures, leading to a better quality of life and greater peace of mind. For the healthcare system, it represents a path toward greater efficiency and more durable clinical results.

The significance of these findings is being recognized by the broader cardiology community. Dr. Anić is scheduled to deliver a “Spotlight” presentation on the PFAnalyzer at the upcoming AF Symposium, a major international conference for arrhythmia specialists. CathVision will also present several related posters detailing the technology’s ability to assist in catheter placement and evaluate electrode contact, further underscoring its utility as a comprehensive guidance tool.

Navigating a Crowded and Competitive Market

While CathVision’s technology is promising, it enters a fiercely competitive market. However, the company’s strategy appears to be one of differentiation. Rather than producing another PFA catheter, it is providing a crucial intelligence layer that could potentially enhance the performance of any PFA system. By focusing on superior signal acquisition and analytics, CathVision is positioning itself as an essential partner in the quest for procedural excellence.

It is important to note, however, that the path to widespread clinical use is still in progress. The company’s press release clearly states that the PFAnalyzer™ module is not yet approved for sale. Like all novel medical devices, it must undergo rigorous review and validation through clinical trials to gain regulatory clearance from bodies like the U.S. Food and Drug Administration (FDA) and European authorities.

This step is critical for ensuring the technology is both safe and effective before it can be commercialized. As the field of electrophysiology continues its rapid evolution away from purely anatomical targets and toward a more data-driven, functional approach, the ability to interpret the heart’s subtle electrical language is becoming paramount. CathVision’s work represents a key step in that direction, pushing the boundaries of what is possible in the treatment of cardiac arrhythmias.